Secondary Logo

Journal Logo

Vaccines and immune globulins

Bridgeman, Mary Barna PharmD, BCPS; Dalal, Kavitha S. PharmD

doi: 10.1097/01.NURSE.0000482257.48273.02
Department: DRUG CHALLENGE
Free

Mary Barna Bridgeman is a clinical associate professor at Rutgers University Ernest Mario School of Pharmacy in Piscataway, N.J. Kavitha S. Dalal is a critical care pharmacist at Virtua in Marlton, N.J.

Unless otherwise specified, the information in the preceding summaries applies to adults, not children. Consult the package insert for information about each drug's safety during pregnancy and breastfeeding. Also consult a pharmacist, the package insert, or a comprehensive drug reference for more details on precautions, drug interactions, and adverse reactions.

Can you identify these common vaccines or antibody preparations? Match the products in Section I with the indication or disease it protects against in Section II.

Back to Top | Article Outline

Section I

_____ 1. Flublok (Protein Sciences)

_____ 2. Menveo (Novartis)

_____ 3. VariZIG (Cangene)

_____ 4. Hiberix (GlaxoSmithKline)

Back to Top | Article Outline

Section II

a. Influenza virus subtypes A and type B. This trivalent influenza vaccine contains the antigens of three different strains of the influenza virus. It's approved for use in adults age 18 or older and contains no egg proteins, making it a safe option for those with egg allergies. Gently shake the single-dose vial before withdrawing the dose and administering it, preferably in the deltoid muscle.

b. Varicella zoster. This immune globulin product is indicated for postexposure prophylaxis against varicella zoster infection in high-risk patients, such as immunocompromised children and adults, infants less than age 1 year, and pregnant women. It's intended to reduce the severity of varicella viral infections. Product dosing depends on body weight. Administer this product I.M. at one or two injection sites, depending on the dose.

c. Meningococcal disease. Indicated to prevent disease caused by certain serogroups of Neisseria meningitidis, this vaccine is approved for use in patients ages 2 months through 55 years. Reconstitute the dose immediately before administering it. A single I.M. dose after reconstitution is 0.5 mL.

d. Haemophilus influenzae type b. Administer this vaccine to prevent infection in children ages 6 weeks through 4 years (prior to the fifth birthday). As recommended, give primary doses at ages 2, 4, and 6 months, and a booster dose at 15 to 18 months. The first dose can be given to infants as young as 6 weeks.

ANSWERS: 1a, 2c, 3b, 4d

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.